FDA Greenlights Novel Combination Therapy for Relapsed Multiple Myeloma
The Food and Drug Administration has approved teclistamab-cqyv in combination with daratumumab hyaluronidase-fihj for adults battling relapsed or refractory multiple myeloma, offering a new treatment option for patients who have already undergone at least one prior line of therapy. This approval also expands the use of teclistamab as a standalone treatment for those who have experienced relapse after at least four previous therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.
Breakthrough Results from the MajesTEC-3 Trial
The FDA’s decision is based on compelling data from the phase 3 MajesTEC-3 trial. The trial demonstrated a significant 83% reduction in the risk of disease progression or death compared to standard care regimens. Specifically, patients receiving the teclistamab-daratumumab combination exhibited a 3-year PFS rate of 83.4%, a substantial improvement over the 29.7% observed in the control group. The 3-year overall survival rate was 83.3% for the combination therapy group, compared to 65% in the control group.
A New Standard of Care?
“This new treatment option can redefine how we approach [relapsed or refractory multiple myeloma] treatment by giving health care providers a regimen with improvement in PFS and OS and a well-characterized safety profile,” stated Luciano J. Costa, MD, professor of multiple myeloma and director of the multiple myeloma research and treatment program at the University of Alabama at Birmingham. He further emphasized the importance of utilizing this regimen earlier in the treatment process, potentially as a second-line therapy, given the tendency for multiple myeloma patients to experience multiple relapses and diminishing responses to subsequent treatments. The steroid-sparing nature of the combination is also expected to reduce toxicity and improve patient tolerability.
How the Trial Was Conducted
The MajesTEC-3 trial involved 587 patients randomly assigned to receive either the teclistamab-daratumumab combination or a control regimen consisting of daratumumab hyaluronidase-fihj with pomalidomide and dexamethasone, or daratumumab hyaluronidase-fihj with bortezomib and dexamethasone. The results clearly favored the combination therapy in terms of both progression-free survival and overall survival.
Understanding the Safety Profile
While highly effective, the treatment is not without potential side effects. Common adverse events observed in patients treated with teclistamab plus daratumumab hyaluronidase-fihj included hypogammaglobulinemia, upper respiratory tract infection, cough, diarrhea, musculoskeletal pain, COVID-19, pneumonia, injection site reaction, fatigue, pyrexia, headache, nausea, gastroenteritis, and decreased weight. Serious adverse events were reported in 70.7% of patients in the combination group, compared to 62.4% in the control group. Treatment discontinuations due to adverse events were slightly less frequent in the combination group (4.6% vs. 5.5%), but grade 5 treatment-emergent adverse events occurred more often (7.1% vs. 5.9%).
The prescribing information for teclistamab includes a boxed warning regarding the potential for life-threatening or fatal cytokine release syndrome and neurologic toxicity, including immune effector cell-associated neurotoxicity.
Future Trends in Multiple Myeloma Treatment
This approval signals a growing trend towards combination therapies in multiple myeloma, leveraging the synergistic effects of different drug classes to achieve deeper and more durable responses. The focus on earlier intervention, as highlighted by Dr. Costa, is also likely to develop into increasingly prevalent. The development of therapies with improved safety profiles, such as those minimizing steroid use, will be crucial for enhancing patient quality of life.
The Role of Targeted Therapies
Teclistamab, a bispecific antibody, represents a significant advancement in targeted therapies for multiple myeloma. Bispecific antibodies are designed to bind to two different targets simultaneously, in this case, a target on myeloma cells and a target on immune cells, effectively bridging the gap and enhancing the immune system’s ability to attack cancer cells. Expect to see continued innovation in this area, with the development of new bispecific antibodies targeting different antigens on myeloma cells.
FAQ
Q: What is relapsed or refractory multiple myeloma?
A: Relapsed multiple myeloma means the cancer has returned after a period of remission. Refractory multiple myeloma means the cancer did not respond to initial treatment.
Q: What are the potential side effects of this treatment?
A: Common side effects include infections, fatigue, and gastrointestinal issues. More serious side effects, such as cytokine release syndrome and neurologic toxicity, are possible.
Q: Is this treatment suitable for all multiple myeloma patients?
A: This treatment is specifically approved for adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.
Q: What is daratumumab hyaluronidase-fihj?
A: Daratumumab hyaluronidase-fihj is an antibody that targets a protein called CD38 on myeloma cells.
Did you know? The FDA approval of this combination therapy was facilitated by the Commissioner’s National Priority Voucher pilot program, recognizing its potential to address an unmet medical need.
Pro Tip: Discuss all potential treatment options and their associated risks and benefits with your oncologist to make an informed decision that is right for you.
Stay informed about the latest advancements in multiple myeloma treatment by exploring additional resources on Healio and consulting with your healthcare provider.
